Clinical Advances in Nasopharyngeal Carcinoma - Episode 5

Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

, ,

Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.

EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach
EP. 2: Current Guidelines for Managing Nasopharyngeal Carcinoma
EP. 3: Overview of the JUPITER and POLARIS-2 Trials
EP. 4: Value of PD-L1 Biomarker in NPC
Now Viewing
EP. 5: Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab
EP. 6: Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors
EP. 7: Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment
EP. 8: Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma
EP. 9: Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects
EP. 10: Clinical Scenario: Locally Recurrent NPC

Video content above is prompted by the following:

  • Please highlight the study design, efficacy, and safety data of the phase 3 DIPPER trial.
    • What are your thoughts on the data and how might this impact the current treatment landscape?

Related Content:

Clinical Advances in Nasopharyngeal CarcinomaYale Cancer CenterCity of HopeHead & Neck CancersInsights
Dr Amanam on the Optimal Use of JAK Inhibitors in the Current Myelofibrosis Treatment Paradigm
Clinical Scenario: Locally Recurrent NPC
Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects